Vivos Therapeutics VVOS 深 沪
已收盘 09-19 16:00:00 美东时间
3.44
+0.100
+2.99%
华盛通- 最 高3.5699
- 今 开3.33
- 成交量 24.98万股
- 最 低 3.3058
- 昨 收 3.34
- 总市值 2581.65万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 3.33%
- 52周最低 1.98
- 委 比 98.69%
- 总股本 750.48万
- 历史最高 360.25
- 量 比 0.20
- 振 幅 7.91%
- 历史最低 1.91
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics Announces Peer-Reviewed Published Data Confirming That Vivos DNA Is Both Safe And Efficacious In Treating Children Suffering From OSA
Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for
09-17 20:34
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics' Vivos DNA appliance, part of the C.A.R.E. line, has been proven safe and effective in treating children with obstructive sleep apnea (OSA) in a multicenter clinical trial published in *The European Journal of Pediatrics*. The study showed that 77% of participants experienced at least a 50% reduction in OSA severity, and 93% of severe cases achieved this reduction. The appliance increases airway volume by 67.8% and reduces slee...
09-17 12:30
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.5
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $6.2 to $6.5.
09-09 19:18
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers OSR Holdings (NASDAQ:OSRH) shares rose 34.6% to $0.7 during Friday's a...
08-23 05:07
Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.35) by 57.14 percent. This is a 8.33 percent increase over losses of $(0.60) per share
08-20 04:23
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. will release its Q2 2025 financial results after market close on August 19, 2025, followed by a conference call at 5:00 pm ET to discuss results and recent developments. The call can be accessed by dialing (800) 717-1738 (US) or (646) 307-1865 (int'l), with a replay available until September 2, 2025. A live webcast and archive will be available on Vivos' website. The company focuses on treating sleep-related breathing dis...
08-19 12:30
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
<p>Vivos Therapeutics, Inc. (NASDAQ: VVOS) 宣布两项关键任命——Michael Bruhn 担任执行副总裁，负责业务整合运营，以及 Dr. Terry Jones 任高级副总裁，负责人力资源，以支持其在睡眠测试中心和患者治疗服务方面的扩展。Bruhn 将推动公司在东海岸的业务扩展及新收购的整合，而 Jones 则将加强公司的人力资源管理。两人的加入体现了 Vivos 在新业务模式下快速增长的承诺。Vivos 目前正在积极寻求类似收购以提升收入。</p>
07-30 12:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
